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KESAN IMUNOMODULATORI ASID ASIATIK DAN MADEKASSOSID 
Centella asiatica (PEGAGA) TERHADAP TITISAN SEL MAKROFAJ 




Makrofaj memainkan peranan penting dalam imuniti semulajadi bagi 
menghalang atau merawat badan daripada jangkitan. Jangkitan adalah ketaknormalan 
yang disebabkan oleh mikroorganisma dan pada masa sekarang, jangkitan ini di 
kawal oleh pelbagai ubat sintetik. Namun demikian, kebanyakan ubat sintetik yang 
sedia ada menunjukkan banyak kesan sampingan yang buruk dan menyebabkan 
kemunculan kerintangan terhadap agen anti-mikrob dalam kalangan mikroorganisma 
patogenik. Oleh itu, pencarian terhadap pelbagai agen alternatif yang mempunyai 
kebolehan untuk melakukan modulasi sistem imun perlu diterokai. Asid asiatik (AA) 
dan madekassosid (MA) merupakan dua komponen bioaktif utama pentasiklik 
triterpena yang diisolasi daripada Centella asiatica dan mempunyai potensi untuk 
melakukan modulasi pada sistem imuniti berdasarkan kajian yang lepas. Namun 
demikian, tiada data saintifik berkenaan kesan individu dan kombinasi kedua-dua 
komponen ini pada model sel titisan makrofaj mencit J774A.1 yang normal. Oleh 
yang demikian, kajian in vitro ini adalah untuk menguji hipotesis sama ada kedua-
dua komponen ini berkebolehan untuk meningkatkan gerak balas imun semulajadi 
makrofaj. Secara ringkas, makrofaj di kultur dalam lima kumpulan yang terdiri 
daripada makrofaj yang tidak dirawat, makrofaj yang dirawat dengan 
lipopolisakarida sebagai kawalan positif, makrofaj yang dirawat dengan AA induk, 
makrofaj yang dirawat dengan MA induk dan makrofaj yang dirawat dengan 
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kombinasi AA dan MA (AA+MA) dalam masa 24 jam. Hasil dapatan kajian ini 
ditentukan mengunakan asai MTT, kaedah pemerhatian pada perubahan morfologi 
sel, tindak balas rantai polimerase transkriptase berbalik (RT-PCR) dan pemblotan 
Western. Selain itu, slaid pewarnaan Giemsa juga digunakan untuk menilai aktiviti 
fagositik. Asai “enzyme-linked immunosorbent” (ELISA) dan Griess juga 
dilaksanakan untuk menentukan penghasilan sitokin inflamatori dan nitrit oksida 
(NO) dalam supernatan makrofaj yang dirawat tersebut. Keputusan yang diperolehi 
menunjukkan rawatan induk MA dan kombinasi AA+MA tidak menunjukkan 
sebarang kesan sitotoksik yang signifikan terhadap makrofaj. Kombinasi rawatan 
AA+MA pada dos (25+25) μg/mL meningkatkan secara signifikan pengekspresan 
mRNA dan protein reseptor “toll like” 2 (TLR-2) dan TLR-4, aktiviti fagositosis, 
pengekspresan mRNA dan penghasilan sitokin inflamatori, penghasilan mediator 
iaitu rembesan NO dan pengekspresan sintase nitrit oksida teraruh (iNOS) serta 
pengekspresan semua protein yang terlibat di dalam laluan isyarat gerak balas 
inflamatori iaitu “myeloid differentiation primary response 88” (MyD88), “c-Jun N-
terminal kinases 1 dan 2” (JNK 1/2), “extracellular signal-regulated kinases 1” (ERK 
1/2) dan p38 apabila dibandingkan dengan makrofaj yang tidak dirawat serta 
makrofaj yang dirawat dengan setiap komponen induk AA dan MA (50 μg/mL) 
(p˂0.0001). Kesimpulannya, penemuan kajian ini menunjukkan rawatan kombinasi 
AA+MA berkebolehan untuk meningkatkan gerak balas imun semulajadi makrofaj. 
Penemuan kajian ini mencadangkan pengambilan kedua-dua komponen ini sebagai 
makanan tambahan secara kerap akan sentiasa merangsang pengaktifan sistem imun 
bagi mencegah potensi jangkitan. 
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IMMUNOMODULATORY EFFECTS OF ASIATIC ACID AND 
MADECASSOSIDE OF Centella asiatica (PEGAGA) ON J774A.1 MOUSE 
MACROPHAGE CELL LINE 
ABSTRACT 
 
Macrophage plays a vital role in innate immunity to prevent or treat the host 
from infection. Infection is an ailment which initiated by various pathogenic 
microorganisms and managed by many therapeutic synthetic drugs. However, almost 
available synthetic drugs presented with many adverse side effects and caused to the  
emergence of anti-microbial resistance among pathogenic microorganisms. 
Therefore, alternative agents that promote immunomodulatory activities needs to be 
explored. Asiatic acid (AA) and madecassoside (MA) are two main bioactive 
components of pentacyclic triterpenes isolated from Centella asiatica have this 
immunomodulatory potential based on the previous studies. However, there is no 
scientific data related to the effects of these individual and combination compounds 
on normal model of J774A.1 mouse macrophage cell line. Therefore, this in vitro 
study tested the hyphothesis whether both compounds are able to elicit an innate 
immune function of macrophages. Briefly, macrophages were cultured in five 
groups; untreated macrophage, macrophage-treated with lipopolysaccharides as a 
positive control, macrophage-treated with single AA, macrophage-treated with single 
MA and macrophage-treated with combination AA and MA (AA+MA) for 24 hours. 
The immunomodulatory effects of these compounds were determined using MTT 
assay, an observational method for cells morphological changes, reverse 
transcriptase-polymerase chain reaction (RT-PCR) and Western blot analysis. In 
addition, Giemsa staining was also used to assess the phagocytic activity while 
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enzyme-linked immunosorbent assay (ELISA) and Griess assay were used to 
determine the production of pro-inflammatory cytokines and nitric oxide (NO) in 
culture supernatants of treated macrophages, respectively. The results showed both 
single MA and combination treatments of AA+MA did not exert any cytotoxic 
effects on macrophages. Furthermore, the combination treatments of AA+MA at a 
dosage of (25+25) μg/mL were significantly enhanced the mRNAs and proteins 
expression of TLR-2 and TLR-4 receptors, phagocytosis activity, mRNAs expression 
and production of pro-inflammatory cytokines, production of  mediators; NO 
secretion and inducible nitric oxide synthase (iNOS) expression as well as expression 
of proteins involved in the signalling pathway of inflammatory response including 
myeloid differentiation primary response 88 (MyD88), c-Jun N-terminal kinases 1 
and 2 (JNK 1/2), extracellular signal-regulated kinases 1 (ERK 1/2) and p38 as 
compared to the untreated macrophages and each single compound of AA and MA-
treated macrophages (50 μg/mL) (p˂0.0001). In summary, the findings suggest that 
the combination treatments of AA+MA are able to upsurge innate immune responses 
of macrophages. The findings of this study suggest that the regular consumption of 
these compounds as a food suplement will continuously stimulate the immune 







1.1 Background of Study 
 
The immune system which comprises of innate and adaptive immunity plays 
a crucial role in human health as it protects the body from invading pathogens and 
treats existing diseases (Konradt and Hunter, 2018). Resultantly, a minor infection 
can already trigger severe disease in the host if it has defected or fragile immune 
system (Spoor et al., 2019). Therefore, it is believed that the development of 
abnormal conditions such as infection and cancer are related to the alteration and the 
weakness of the host’s immune system (Fleming-Davies et al., 2018; Weksler and 
Lu, 2014). One of the ways to reduce this problem is to modify the host’s immune 
responses by increasing the competency of this system in preventing or eliminating 
the aetiological agents that cause diseases (Aspinall and Lang, 2018). As a 
consequence, the modification of immune responses that function to increase or 
lower the immune alertness which is also known as immunomodulation to treat 
diseases through potential agents has been a great discovery to explore (Hadden, 
1987). As an example, the modulation of primary or innate immunity has a major 
influence on the host’s capability to react rapidly and effectively to a diverse group 
of pathogens that caused diseases (Thakur et al., 2019).  
 
In order to acquire a better understanding of the immunomodulatory effects 
of potential agents such as plant compounds, the researcher must consider its effects 
on the immune cells which function to regulate immunity in a body. One of the most 
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important cells is macrophage which is a key player and the main component of 
innate immunity that is involved in the initial protection against pathogenic 
microorganisms that encounter the host (Byrne et al., 2015; Weiss and Schaible, 
2015). Resident macrophages always present in the tissue such as gastrointestinal 
tract (Grainger et al., 2017), lung (Gordon and Read, 2002), liver, bone and skin 
(Davies et al., 2013). The functions of specific pathogen recognition receptor (PRR) 
expresses on the cell surface of macrophage are to recognise and interact with the 
various components of a pathogen associated molecular pattern (PAMP) on 
microorganisms. These processes activate the macrophage and enhance its responses 
towards stimuli (Leavy, 2015). 
 
Additionally, activated macrophage ingests microorganisms into vesicles 
through a specific process called phagocytosis (Masud et al., 2019). Subsequently, 
stimulated macrophage plays a key role in the primary immune responses by 
producing various pro-inflammatory cytokines including interleukins and chemokine 
to eradicate infectious agents and tumour (Moghaddam et al., 2018). The production 
of these substances promotes further cellular reactions of innate immunity that serve 
to kill and degrade the pathogenic microorganisms that have encountered the host 
(Duque and Descoteaux, 2014). Tumour necrosis factor-alpha (TNF-α), interleukin 
(IL)-1-beta (IL-1β), IL-12 and IL-6 are the secreted pro-inflammatory cytokines 
involved in host protection against infection (Nonnenmacher and Hiller, 2018). Pro-
inflammatory cytokines also stimulate macrophage to produce toxic reactive nitric 
and oxygen species that consist of nitric oxide (NO) and hydrogen peroxide (H2O2) 
for intracellular killing (Nathan and Hibbs, 1991; Trujillo and Radi, 2019). Activated 
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macrophage is also plays a role as an antigen presenting cells to stimulate T helper 
lymphocyte in adaptive immune response (Roche and Furuta, 2015).  
 
Activation of innate immune responses of macrophage towards pathogens is 
also regulated by the intracellular inflammatory signalling pathway (Newton and 
Dixit, (2012). Initially, the interaction of PAMP with toll-like receptor (TLR) which 
is a part of PRR promotes downstream inflammatory signalling pathways via 
myeloid differentiation primary response 88 (MyD88) adaptor proteins. This 
receptor-ligand interaction leads to the activation of mitogen-activated protein 
(MAP) kinases involved in this pathway and further promotes the phosphorylation of 
MAPkinases activator protein-1 (AP-1) (Vidya et al., 2017). MAPkinases consist of 
extracellular signal-regulated protein kinase 1/2 (ERK 1/2), c-Jun N-terminal kinases 
1/2 (JNK 1/2) and p38 MAP kinases (p38) which regulate various cellular functions 
differentially including activation of macrophage (Arthur and Ley, 2013). On top of 
that, AP-1 is a transcription factor that coordinates the expression of genes that 
encode inducible nitric oxide synthase (iNOS), IL-12p40, IL-1β and TNF-α 
(Lloberas et al., 2016). iNOS catalyses the generation of NO, a molecule secreted by 
macrophage which plays a key role in the innate immune responses (Bogdan, 2015).  
 
Infectious disease (ID) is caused by various pathogenic microorganisms consist 
of bacteria, viruses, parasites and fungus (Krumkamp et al., 2015). The severity of 
ID is closely related to the capability of the host immune response to resolve the 
infections. Hence, it influences the ability of pathogen to establish its existence in a 
host (Sorci et al., 2013). This consequence is related to the finding by Li et al., 
(2016) suggested that the pattern of infectious disease was related to the decrease of 
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immunity and malnutrition in younger and elderly groups which led them susceptible 
to infections, increased the severity and facing poor progress after treatment. 
Presently, public awareness regarding ID has been increased due to various factors 
such as rapid spread of diseases, high incidence of morbidity and mortality and slow 
development of vaccines. Economically, the management of ID is very costly 
(Cunningham et al., 2017). The common current clinical therapies for management 
of ID are mainly based on the elimination of the aetiologic pathogen that triggers the 
diseases and to release the symptoms by using synthetic medicinal drugs (Shane et 
al., 2017). However, the synthetic drugs were caused several adverse side effects and 
emergence of anti-microbial resistance among the pathogenic microorganisms 
(Dyson et al., 2019). According to World Health Organisation (WHO), the 
occurrence of anti-microbial resistance is growing in both hospitalised patients and 
community and depends on the effectiveness of anti-microbial agents as well as the 
spread of resistant pathogens among patients (WHO, 2000). 
 
The use of natural products and their derivatives as a source of 
immunomodulation agents has become increasingly important nowadays due to the 
adverse side effects of the drugs used in the clinical setting. Immunostimulants from 
natural products as a potential agents are considered beneficial to prevent or treat 
bacterial and viral infections (Chauhan et al., 2014; Park et al., 2018) as well as in 
cancer (Park et al., 2013) which is caused from immunodeficiency conditions.  
 
Asiatic acid (AA) and madecassoside (MA), two important bioactive 
pentacyclic triterpenes which derived from Centella asiatica that contribute to the 
various valuable medicinal properties of this plant (Mahmood et al., 2016). Based on 
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the previous studies, these compounds possesses a wide range of biological functions 
including anti-microbial (Idris and Nadzir, 2017), immunomodulatory (Jayathirtha 
and Mishra, 2004), anti-inflammatory, anti-oxidant (Nurlaily et al., 2012) and anti-
cancer activities (Zhang et al., 2013). Instead of being majorly found in C. asiatica, 
AA also can be isolated from other plants such as from Salvia miltiorrhiza (Tung et 
al., 2017), Psidium guajava (Anand et al., 2020), Punica granatum (Arun and Singh, 
2012), Averrhoa carambola, Gynura bicolor and  Brassica juncea (Yin, 2015).  
However, based on the literature, AA from C. asiatica has gained more interest 
among researcher to study for its pharmacological activities. Therefore, in the present 
study, AA and MA from C. asiatica were selected and tested in single and 
combination treatments on mouse macrophage cell line to evaluate their 
immunomodulatory effects on innate immune functions of this cell. 
1.2 Problem Statement  
 
ID receives the highest concern among healthcare providing organisation, 
mainly in developing countries (WHO, 2000). It is mainly managed through 
preventive measures including vaccination (Maslow, 2017) as well as using suitable 
synthetic medicinal drugs such as antibiotics and anti-viral to treat the existing 
diseases (Bekerman and Einav, 2015). However, antibiotic has many serious adverse 
effects such as allergic reactions and removal of normal flora bacteria in the body 
(Glick, 2016). Additionally, Tamma et al., (2017) also had stated that there were 
adverse conditions such as nausea, vomiting, anaphylaxis, hematologic and 
neurological abnormalities within 30 days of antibiotic initiation among hospitalised 
patients. Furthermore, there is also antibiotic resistance among enteric pathogens and 
it is a common cause of gastrointestinal infection in human. Research finding by 
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Shields et al., (2016) showed that 30 % of resistant cases had been detected among 
carbapenem-resistant Enterobacteriaceae infected patients which exhibited re-current 
infections after consuming ceftazidime-avibactam drug. Likewise, the consumption 
of this drug also promotes acute kidney injury which was also detected in three out of 
31 patients within seven days prior to treatment. 
 
Thus, other alternative for immunomodulatory agents from other sources 
such as natural products receive more interest among researchers. It is because the 
specific agents have the potentials to elicit the normal body’s immune defence 
system to provide  improved protection against microbial infection. Besides, 
immunomodulatory therapies also provide benefits by targeting the host than the 
specific pathogen which later would reduce the incidence of microbial resistance 
(Hancock et al., 2012). 
 
1.3 Rationale of Study 
 
There is a large cluster of various bioactive compounds with significant 
amounts of pharmacological activities originated from medicinal floras and herbs. 
These beneficial compounds which contained specific bioactivities are beneficial in 
promoting human health. In 2013, 1453 new bioactive compounds have been 
patented from natural products approved by the US Food and Drug Administration 
(Katz and Baltz, 2016). They have been widely used as health supplements, nutritive 
products and medications since pre-historic time. Natural product-based drugs 
promote the significant role in the pharmaceutical industry. Lately, safe drugs with 
low side effects and enclosed with chemical molecules that act as selective ligands to 
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effectively prevent and cure diseases have become a mission for drug development 
programs (David et al., 2015).  
 
 In Malaysia, C. asiatica is regularly consumed either in the form of products 
or eaten raw as a salad by a general healthy population with a lack of scientific 
evidence related to the immunomodulatory activities of this plant in healthy 
experimental models. Thus, it is believed that C. asiatica has a potential to modulate 
the innate immune responses of resident macrophages in a body which acts as a 
prevention against pathogenic microorganisms that can cause numerous ID. 
Expecting the potential of AA and MA as the major compounds in C. asiatica that 
able to modulate the immune responses in the previous scientific investigations, they 
have been chosen as the main interest in this study. As far as our literature survey 
could ascertain, there has been no scientific data related to the effects of these 
individual and combination compounds on the normal model of mouse macrophage 
cell line (J774A.1). Hence, by using this model, the present study was conducted to 
determine the effects of single AA, MA and their combination (AA+MA) on the 
innate immune responses of macrophages. Hopefully, this study will provide initial 
knowledge in the development of a novel preventive agent to specifically enhance 
the innate immune responses of the host and presents an ideal strategy for 
preparation and protection of the host against invasion of various agents that can 
cause ID rather than treating existing diseases.   
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1.4 Objectives of Study 
1.4.1 General objective 
To evaluate the immunomodulatory activities of asiatic acid (AA) and 
madecassoside (MA) derived from Centella asiatica on the innate immune responses 
of J774A.1 mouse macrophage cell line. 
1.4.2 Specific objectives 
1. To evaluate the cytotoxicity of individual and combination of AA and MA 
treatments on J774A.1 mouse macrophage cell line by determining the viability 
percentage and morphological changes. 
 
2. To evaluate the effects of individual and combination of AA and MA treatments 
on innate immune responses of J774A.1 mouse macrophage cell line. 
i. To determine the messenger ribonucleic acids (mRNAs) expression of 
TLR-2, TLR-4 and their proteins expression. 
ii. To determine the phagocytosis activities, the production of NO and 
expression of iNOS protein. 
iii. To determine the mRNAs expression of pro-inflammatory cytokines (IL-
1β, IL-12p40, TNF-α) and their proteins production. 
 
3. To evaluate the effects of individual and combination of AA and MA treatments 
on the expression of MyD88 protein and MAPkinases (ERK 1/2, JNK 1/2 and 
p38) that involved in the inflammatory signalling pathway in J774A.1 mouse 




The hypotheses of this study are: 
 
1. The individual and combination treatments of AA and MA show non-cytotoxic 
on J774A.1 mouse macrophages cell line.  
2. Combination treatments of AA and MA increase all the innate immune 
responses of J774A.1 mouse macrophages cell line when compared to the 
untreated and individual groups. 
3. Combination treatments of AA and MA enhance the expression of targeted 
proteins of J774A.1 mouse macrophages cell line involved in MAPkinases 
signalling pathway when compared to the untreated and individual groups. 
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1.6 Flowchart of the Study 
 
 





2.1 Overview of Immune Systems 
 
An immune system consists of a group of cells, molecules and tissues that 
facilitate the resistance to infections (Delves and Roitt, 2000). The important 
function of the immune system is to prevent from future infections (Keller and 
Stiehm, 2000) and to eliminate established infections which are already presented in 
the host (Weiss and Schaible, 2015). There are other roles of the immune system 
including recognising and responding to newly introduced proteins and tissue grafts 
which are important in transplantation (Zeiser et al., 2019). In addition, the immune 
system also plays a crucial role in host protection against tumor as it has postive 
potential in cancer immunotherapy (Yang, 2015). 
 
The mammalian defence systems are divided into two which are innate 
immunity and adaptive immunity as showed in Figure 2.1. The anatomic and 
physiological barriers, such as intact skin, special lysozyme; saliva and tears as well 
as acidic pH of the stomach offer the initial line of protection against diverse 
pathogens (Turvey and Broide, 2010). Innate which is also known as primary or 
natural immunity involves specific immune cells that mediates the first protection to 
human body, quick respond to pathogens and boost the protection offered by the 
natural immune barriers (Lambrecht and Hammad, 2014). On the other hand, 
macrophage and dendritic cell have a distinct role as an antigen-presenting cells  in 
adaptive immunity (Hespel and Moser, 2012; Weiss and Schaible, 2015). In brief, 
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adaptive immunity consisting of B and T lymphocytes that facilitate later actions as a 






Figure 2.1 Cellular components of the mammalian immune system. Modified 
from Nicholson (2016) and Yamauchi and Moroishi (2019). 
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2.1.1 Innate immunity defence 
 Innate immunity is a natural task performed especially by hematopoietic-
originated cells including macrophage, neutrophil, dendritic, eosinophil, and natural 
killer (NK) cell. This type of defence depends mainly on the cells that able to 
recognise microbes, move towards them, picking them by phagocytosis and kill them 
(Spiering, 2015). Likewise, there are also significant roles of non-hematopoietic 
originated cells that consist of specialised epithelial cells barriers that function in the 
early immune response towards encountered pathogens (Turvey and Broide, 2010). 
For instance, the gut barrier is the largest component compare to others and 
particularly adaptable to colonisation by gut microbiota. Its function is to help in 
digestion and contributes to the improvement and role of the mucosal immune 
system (Ahluwalia et al., 2017). However, the disruption of the  barriers caused by a 
pathogenic microorganism leads to infection in the gastrointestinal tract (Peterson 
and Artis, 2014). 
 
  The dynamic mechanism of innate immune responses towards microbial 
infection and tissue injury is known as inflammation. The effective inflammatory 
responses provide a wide-ranging protection against infections and later coordinate 
long-standing to acquire immunity toward specific pathogens (Xiao, 2017). A normal 
inflammatory response involves four components; inflammatory triggers, detection 
receptors, inflammatory cytokines and mediators which are regulated by different 
inflammatory pathways (Medzhitov, 2010). The initial immune response is crucial 
for early pathogen recognition which is related to genetically predetermined 
germline-encoded receptors on their immune cells known as pathogen recognition 
receptor (PRR) (Tartey and Takeuchi, 2017). These non-specific receptors recognise 
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either conserved structures expressed by various classes of microbes or other 
molecules released during infection. There are many microbial ligands originated 
from structural components of bacteria, fungi, viruses and other biosynthetic 
molecules such as nucleic acids that can be recognised by PRR and further activate 
the immune cells like macrophage and dendritic cell (Brubaker et al., 2015). As a 
result, cell activation promotes stimulation of innate immune responses through the 
process of opsonisation and phagocytosis as an initial host protection against 
infection (Brubaker et al. 2015; Kawai and Akira, 2010). 
 
Additionally, during phagocytosis the involved immune cells also produce 
numerous pro-inflammatory cytokines such as TNF and IL-1 that function to recruit 
and activate other intravascular leukocytes (Carrero et al., 2012) as well as to 
stimulate the maturation of dendritic cells to further enhance the adaptive immune 
responses (Steinbach and Plevy, 2015). These cytokines also function to vasodilate 
the local blood vessel at the targeted tissues for neutrophils migration to the site of 
infection which involve a multistep process (Fink and Campbell, 2018). Besides, 
TNF and IL-1 also stimulate the endothelium of small vessels at the site of infection 
to rapidly express two adhesion molecules called as P-selectin and E-selectin which 
act as a ligand for integrin and chemokines (Konradt and Hunter, 2018). The 
tethering and rolling of blood neutrophils on the endothelium are mediated by both 
adhesion molecules (Gong et al., 2017). 
 
Neutrophils activation and their migration via endothelium to the site of 
infection also activated by chemokine (Turner et al., 2014). Chemokine constitute a 
large family of low molecular-weight of cytokine which is secreted in response to 
pathogens and other inflammatory stimuli. The production of chemokine is regulated 
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by NO and prostaglandin (Kobayashi, 2010). The high concentration of chemokine 
bound on the luminal surface of endothelial cells displayed to the leukocytes. This 
chemokine enhances the motility of leukocytes and their integrin’s affinity to the 
ligands on the endothelium Consequently, leukocytes start to migrate along the 
chemokine concentration gradient and perform diapedesis between endothelial cell 
wall to the site of infection (Pilar et al., 2017). Meanwhile, IL-12 functions to 
stimulate T helper lymphocytes and promotes cell-mediated immunity to combat the 
pathogens and cancer that established in a host (Duque and Descoteaux, 2014). 
 
At the site of infection, neutrophils undergo apoptosis after performing roles to 
kill pathogens. Meanwhile, monocytes evolve into macrophages. The apoptotic 
neutrophils are then cleared by macrophages to resolve the inflammation (Newton, 
and Dixit, 2012). Besides, the production of pro-inflammatory cytokines also 
stimulates the macrophages and dendritic cells to destroy the phagocytosed 
pathogens through intracellular killing by releasing toxic substances (Duque and 
Descoteaux, 2014; Forrester et al., 2018; Mosser and Edwards, 2008). Meanwhile, 
eosinophil, basophil and mast cell are essential components of allergic inflammation 
(Stone et al., 2010). Besides,  resident eosinophils in tissue are specifically involved 
in host responses against helminth infection (Weller and Spencer, 2017). 
 
Unfortunately, there are times when pathogens are able to rapidly multiply in a 
host and undergo a revolution to escape the defence mechanisms in the innate 
immune system (French et al., 2004). Nevertheless, the sophisticated and efficiency 
of the innate immune system have been developed further to identify the microbial 
components and link them to  adaptive immunity. Therefore, this prevents the severe 
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pathogenesis caused by pathogens in a host (Thimme et al., 2006; Turvey and 
Broide, 2010).  
2.1.1 (a)  Macrophage  
 
Macrophage has gained a great interest within the previous decade and 
currently their role in the stimulation of innate immunity to prevent ID is getting 
appreciated (Schepetkin and Quinn, 2006). Macrophage or mononuclear phagocyte is 
majorly found in connective tissues and every organ in the body (Epelman et al., 
2014) and this cell also widely known as professional phagocyte in which it 
expresses a multitude of receptors on its surfaces (Murray and Wynn, 2012). 
Normally, the size of peritoneal macrophage is about 10 to 30 µm in diameter and its 
cytoplasm contains basophilic vacuoles and ovoid nucleus (6 to 12 µm in diameter). 
Peritoneal macrophage contains dark gray rod-shaped mitochondria and light gray 
diffuse cytoplasm that can be observed via phase contrast microscopy. Meanwhile, 
the appearance of vacuoles and granules is influenced by physiological state of the 
macrophage (Elhelu, 1983).  
 
Macrophage is derived from precursor cells in the bone marrow that develop 
into monocyte in the peripheral blood before being matured, entering and residing in 
the specific tissues in the human body (Mass, 2018). Stem cells of the granulocytic–
monocytic lineage in the bone marrow that exposed to cytokines such as the 
granulocyte macrophage colony-stimulating factor and IL-3 stimulate the production 
of monocytes (Kumar and Bhoi, 2017). The monocyte presented by approximately 5 
to 10 % of leukocytes in peripheral blood and its size and nuclear morphology is 
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varied and has dissimilar amounts of granularity (Gordon and Taylor, 2005). The 
macrophage that involve in a regulation of inflammatory responses is known as M1 
macrophage while M2-type macrophage reduces this activity and increase the tissue 
healing process (Liu et al., 2014). 
 
There are various homeostatic functions of tissue macrophage and depending 
on its location in a body (Ginhoux and Jung, 2014). For instance, macrophage reside 
in the intestinal and colon of gastrointestinal tract which is the major population of 
mononuclear phagocyte in the body (Hine and Loke, 2019) performs an essential 
role in defence and homeostasis in intestinal circulation system (Grainger et al., 
2017). The bacteria and antigens that breach the epithelial barrier activate the gut 
macrophages to regulate inflammatory responses as a protection against harmful 
pathogenic microorganisms (Smith et al., 2011) as well as to eliminate foreign 
debris and dead cells (Hirayama and Iida, 2018). 
 
The resident macrophage recognise the infectious microbes via interaction of 
TLR-PAMP (Zhou et al., 2016) and complement receptor-opsonised pathogen 
(Bohlson et al., 2014). The interaction initiates the phagocytosis process which leads 
to the enhancement of transcription factors involved in the expression of genes 
encoding specific enzymes, proteins and pro-inflammatory cytokines. All the 
signalling molecules are involved in the anti-microbial tasks of activated macrophage 
(Kawasaki and Kawai, 2014). An activation of macrophage in enhancing phagocytic 
and microbicidal activities is the main element in host’s initial immune responses to 
a diverse array of pathogens. This stage is very important to prevent the host from 
infection or to control the spread of invading pathogens (Mosser and Edwards, 
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2008). An active macrophage also performs antigen presentation to the adaptive 
immune system (Arnold et al., 2015). Moreover, macrophage also contributes to the 
degradation of apoptotic cells and neoplastic cells (Grainger et al., 2017).  
 
 There are numerous macrophage-like cell lines that have been developed for 
in vitro study such as cytotoxicity assessment, mechanisme of surface receptors, anti-
microbial, anti-cancer and immunomodulatory (Paradkar et al., 2017). Based on 
Saleh and Bryant (2018), the benefit of using cell line is it is ready to use for testing 
as well as having high stability in culture. Murine macrophage (J774A.1) that used in 
this study is a secondary transformed and immortalised cell line (Chamberlain et al., 
2015). This cell is always involved in initial testing and screening of plant extracts 
and bioactive compounds on the immune parameters before proceeding to animal 
and clinical studies (Chalons et al., 2018; Machado et al., 2019; More and Pai, 2011; 
Szliszka et al., 2013). 
2.1.1 (b) Pathogen recognition receptor (PRR) 
 
Presently, four  different groups of PRR families have been identified which 
are TLR, nucleotide-binding oligomerisation-like receptor (NLR), C-type lectins 
receptors (CLR), and retinoic acid-inducible gene (RIG)-I-like receptor (RLR) 
(Dowling and Mansell, 2016; Karin and Meylan, 2006; Takeuchi and Akira, 2010). 
Among other classes of PRR, the TLR group is one of the most important PRR 
families for  rapid detection of invading intracellular and extracellular pathogens 
(Aderem and Ulevitch, 2011) and have been widely studied (Dowling and Mansell, 
2016; Mogensen, 2009). This receptor acts as the first responded molecules in innate 
immunity to the existence of the pathogens in a host (Akira and Hemmi, 2003). 
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The role of TLR in innate immune defence was first found in the Drosophila 
model (Vogel, 2012). Mammalian TLR consists of 13 members as presented in Table 
2.1. Ten TLRs (TLR-1 to TLR-10) have been identified in a human and 13 (TLR-1 
to TLR-13) in a mouse (Pandey et al., 2014). TLR functions to recognise  a variety 
of microbial ligands known as PAMP (Akira and Hemmi, 2003) or damage 
associated molecular pattern (DAMP) (Tang et al., 2012). Cellular stress or tissue 
damage caused host cells to release endogenous molecules such as heat shock protein 
which present the most components of DAMPs (Kataoka et al., 2014). Meanwhile, 
PAMPs are molecules shared by the microorganism of the same type that consist of 
lipopolysaccharides (LPS) (Ranf, 2016), bacterial lipoteichoic acids (Morath et al., 
2003), lipopeptides (Takeda et al., 2002), glycolipids (Schick et al., 2017), flagellin 
and zymosan (Aakanksha et al., 2018) which have always been targeted by host’s 
innate immune responses. 
 
Some of TLRs exist in the endosome to recognise the ingested microbes 
(Hemmi et al., 2002; Lester and Li, 2014) and other TLRs are located on the surface 
of the cell membrane to recognise products of extracellular microbes (Ryan et al., 
2011). Then, these recognitions promote TLR-PAMP binding and activate the 
macrophages to enhance innate immune responses in defending the host against 
infection (Brubaker et al., 2015). The function of TLR is important to defense the 
host against pathogens (Savva and Roger, 2013) by stimulating transcription factors 
which further stimulate innate and adaptive immune responses (Peralta et al., 2007; 
Smale, 2015; Takeda & Akira, 2004). In detail, the activation of these transcription 
factors stimulates the secretion of numerous pro-inflammatory cytokines, interferons 
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and mediators (Muzio et al., 2000). Besides, opsonisation and phagocytosis activities 
also enhance in response to the TLR activation (Brubaker et al., 2015). All these 
activities increase innate immune responses of macrophage and further promote its 
anti-microbial responses to prevent the spread of an early infection through 
stimulation of the specific inflammatory signalling pathway (Brightbill and Modlin, 
2000).  
Although there are several TLR expressed by innate immune cells, TLR-2 
and TLR-4 are immensely significant and have gained much interest due to their 
capability to recognise diverse molecular patterns of pathogens that include bacteria, 
viruses, fungi and protozoa (Mukherjee et al., 2016). Thus, the present research 
would determine the effects of targeted compounds on the TLR-2 and TLR-4 
expression of J774A.1 mouse macrophage cell line. 
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Table 2.1 TLRs and their ligands (Behzadi and Behzadi, 2016; 
Mukherjee et al.,2016; Pandey et al., 2014; Takeuchi 
and Akira, 2010; Satoh and Akira, 2016). 
 
Type of TLR Site Ligand Source of the ligand 
TLR-1 Cell membrane Triacyl lipoprotein Bacteria 






TLR-3 Endosome dsRNA Viruses 
TLR-4 Cell membrane LPS and P fimbriae Bacteria, viruses, fungi,  
protozoa 
TLR-5 Cell membrane Flagelin Bacteria 
TLR-6 Cell membrane Diacyl lipoprotein Bacteria, viruses 
TLR-7 
 
Endosome ssRNA Viruses, bacteria, self 
TLR-8 Endosome ssRNA Viruses 
TLR-9 Endosome CpG-DNA Viruses, 
bacteria,protozoa, self 
TLR-10 Endosome Triacyl lipoprotein and  
diacyl lipoprotein 
Bacteria, viruses 
TLR-11 Endosome Profilin-like molecules Protozoa, parasites 
TLR-12 Endosome Profilin-like molecules Parasites 




2.1.1 (b)( i)  Toll-like receptor-2 (TLR-2) 
 
TLR-2 presence on the cell membrane of immune cells like macrophage and 
has a role to recognise common PAMPs of various microorganisms such as 
lipoteichoic acid (Cox et al., 2007), peptidoglycan (Liu et al., 2001), lipoproteins 
(Ihalin and Asikainen, 2018) and zymosan (Underhill and Ozinsky, 2002b) which 
then activates the signalling pathway of an inflammatory response. Besides that, 
TLR-2 is also able to detect certain structural variations of LPS such as those derived 
from  Porphyromonas gingivalis and Leptospira interrogans (Underhill and Ozinsky, 
2002b). TLR-1 and TLR-6 are separately connected with TLR-2 through 
heterodimers and each combination acts differently to identify PAMPs of 
microorganism (Wetzler, 2003). For example, glycosylphosphatidylinositol which 
contains three fatty acid components of Plasmodium falciparum activates 
macrophage effectively through TLR-2/TLR-1 to mediate inflammatory response 
(Zhu et al., 2011). Meanwhile, MyD88/NF-κB signalling pathway was shown to 
stimulate through the interaction of TLR-2/TLR-6 with lactic acid bacteria (Ren et 
al., 2016). 
 
Based on a review study by Mukherjee et al., (2016), several bacteria such 
as Pseudomonas aeruginosa, Staphylococcus epidermidis and Wolbachia induced 
pro-inflammatory cytokines such as TNF-α, IL-12, IL-1 by activation of TLR-2. 
The other cytokines like IL-17 and IL-22 are also secreted through the activation 
of TLR-2/TLR-1 (Nishimori et al., 2012) while the stimulation of TLR-2/TLR-6 
activates the release of IL-10 (Ren et al., 2016). The interaction of TLR-2 with 
microbial ligands stimulates the cytokine production of macrophage via MyD88-
dependent pathway which amplifies MAPkinases (Rojas et al., 2014), NF-kβ (Qin et 
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al., 2016), and phosphoinositide 3-kinases (PI-3K) activations (Lasunskaia et al., 
2006). 
 
2.1.1 (b) (ii) Toll-like receptor-4 (TLR-4) 
 
TLR-4 recognises mainly Gram negative bacterial LPS (Lu et al., 2008) as 
well as other components of pathogens such as teichuronic acid of Gram-positive 
bacteria (Yang et al., 2001) mannuronic acid polymers of Gram-negative bacteria 
(Flo et al., 2002) and F protein from respiratory virus (Kurt et al., 2000). 
Additionally, endogenous molecule such as hyaluronic acid (Ferrandez et al., 2018), 
β-defensin (Feng et al., 2017) and heat shock proteins (Rosenberger et al., 2015) are 
also able to interact either directly or indirectly with TLR-4. 
 
Similar with TLR-2, the interaction of PAMP with TLR-4 receptor leads to 
the activation of their intracellular domain of Toll/interleukin-1 receptor-like (TIR) 
which cause conformational changes in this molecule (Muzio et al., 2000). Then, the 
TIR domain recruits either TIR-domain-containing adapter myeloid differentiation 
factor 88 (MyD88) and MyD88-adapter-like (MAL) which also known as TIR 
domain contain adaptor protein (TIRAP) which involved in MyD88 dependent 
pathway or TIR adapter-inducing interferon-β (TRIF) and TRIF-related adapter 
molecule (TRAM) (MyD88-independent pathway) (Molteni et al., 2016). The 
activation of MyD88-dependent pathway leads to the activation of both MAPkinases 
(Gupta et al., 2017) and nuclear factor kappa beta (NF-κβ) (Tripathi and Aggarwal, 
2006) and further promotes the synthesis of pro-inflammatory cytokines and 
chemokines. In contrast, the type I interferon is induced through activation of 
MyD88-independent pathway (Yamamoto et al., 2003) and depends on the 
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endocyotosis of TLR-4 which requires the presence of CD14 upon microbial 
detection (Zanoni et al., 2011). 
2.1.1(c) Phagocytosis 
 
Phagocytosis is defined as the engulfment of particles with more than 0.5 µm 
in diameter by microorganisms or phagocyte cells. This functional process is 
important for innate immunity and involve numerous signalling pathways (Richards 
and Endres, 2016). Eli Metchnikov, the Father of Innate Immunity, was the first to 
discover the fact that the phagocytic activity of amoeboid cells was related to the 
host defence (Gordon, 2016). Later, the typical models of microbe-innate immune 
interactions were developed for in vitro and in vivo investigations to acquire a better 
understanding regarding this interaction (Tauber, 2003). Phagocytosis is a complex 
process which consisting of uptake, digestion and removal of pathogens and 
apoptotic cells which are important for host defence and tissue homeostasis (Rosales 
and Uribe, 2017). 
 
The phagocytosis process of macrophage is illustrated in Figure 2.2. In brief, 
after binding the specific TLR of macrophage or complement-coated particles with 
PAMP, the phagocytosis process is continued with pathogens that are surrounded by 
membrane protrusion, ingested into membrane-bound vesicle called phagosomes 
which then is fused with lysosomes to make up phagolysosomes (Hirayama and Iida, 
2018; Underhill and Ozinsky, 2002a). The phagocytic processes involved 
cytoskeletal and actin rearrangement to force the particle internalisation (May and 
Machesky, 2001). Lysosome provides enzymes such as phospholipase (Akira et al., 
